161 |
Liver cirrhosis : epidemiological and clinical aspects /Gunnarsdóttir, Steingerður Anna / January 2008 (has links)
Diss. (sammanfattning) Göteborg : Göteborgs universtiet, 2008. / Härtill 4 uppsatser.
|
162 |
Contrasting tumorigenic growth interactions of apoptosis-deficient MYC alleles with Transforming Growth Factor-alpha /Cheung, Ronald Se-Yuen. January 2006 (has links)
Thesis (Ph. D.)--University of Washington, 2006. / Vita. Includes bibliographical references (leaves 92-109).
|
163 |
Investigation of the role of hepatic stellate cells in acute liver failure and hepatocarcinogenesisThompson, Alexandra Inés January 2017 (has links)
Introduction: Hepatic stellate cells (HSC) and myofibroblasts may be relevant stromal drivers of human hepatocellular carcinoma (HCC). It was hypothesised that targeted inhibition of αv integrin-mediated TGF-β activation, by HSC or hepatocytes, may result in reduced peri-tumoural and intra-tumoural extracellular matrix formation, and reduced hepatic carcinogenesis. The role of HSC in acute liver injury is less well characterised. It was anticipated that integrin signalling on HSC and hepatocytes might also be relevant in the acute setting. The emerging technique of intravital microscopy (IVM) allows detailed, real-time investigation of the cellular processes involved in hepatocyte injury, cell death and repair. It was hypothesised that this could be coupled with mouse models of HCC and acute liver injury, to perform sequential imaging under anaesthesia. Aims: (i) To determine the effect of targeted inhibition of αv integrins on HSC and hepatocytes, during hepatocarcinogenesis, in a mouse model of HCC. (ii) To investigate the effect of targeted inhibition of αv and other integrins on HSC, hepatocytes, and liver sinusoidal endothelial cells (LSEC), during acute liver injury, in the mouse model of paracetamol-induced liver injury. (iii) To develop IVM of the liver, via an abdominal imaging window, with optimisation of surgical and imaging techniques, to allow sequential imaging of the same animal. Methods: The diethylnitrosamine (DEN)-induced mouse model of hepatocarcinogenesis was used, and PDGFRβ-Cre;αvfl/fl and Alb-Cre;αvfl/fl mice were employed to deplete αv integrins on HSC and hepatocytes respectively. Tumours were harvested at 40 weeks post-DEN. Tumour size and number was evaluated in all animals. PDGFRβ-Cre;αvfl/fl and Alb-Cre;αvfl/fl mice were used in the paracetamol model, to investigate the role of αv integrins in acute liver injury. PDGFRβ-Cre;β8fl/fl and Alb-Cre;β 8fl/fl animals were also tested in this model. The role of integrins in liver sinusoidal endothelial cells (LSEC) during paracetamol-induced liver injury was evaluated using Cdh5-Cre mice. IVM of the liver was performed by surgical implantation of an abdominal imaging window, consisting of a titanium ring and coverslip, secured in place with a purse string suture. Fluorescent reporter mice were used to identify hepatic and vascular architecture, and other label-free microscope technologies were utilised to image collagen, lipid distribution, necrotic areas and blood flow within tissues. Results: In large cohorts of PDGFRβ-Cre;αvfl/fl, Alb-Cre;αvfl/fl, and control animals, there was no difference in mean tumour size or number, at 40 weeks. Targeted inhibition of α v integrins and β 8 integrin on hepatocytes, HSC or LSEC was not protective in paracetamol-induced liver injury. IVM of the liver can be performed on animals with HCC and throughout paracetamol-induced liver injury, to obtain high quality, real-time images of multiple cell lineages and the hepatic microenvironment. Conclusions: The role of TGF-β in HCC pathogenesis is complex and context-dependent. Targeted loss of αv integrin did not result in reduction in tumour burden in this non-cirrhotic model of HCC. IVM of the liver is a powerful tool to quantify inflammatory infiltrates and assessment of vascular remodelling throughout the course of acute liver injury and regeneration, providing insights into the biological processes determining recovery.
|
164 |
Alcoolização e embolização arterial como terapias-ponte ao transplante hepático no tratamento do hepatocarcinoma relacionado ao vírus da hepatite CChedid, Márcio Fernandes January 2017 (has links)
Racional: O carcinoma hepatocelular é uma neoplasia maligna agressiva com elevada morbidade e mortalidade. Objetivo: Revisão da literatura sobre o diagnóstico e o manejo do carcinoma hepatocelular nos vários estágios da doença. Método: Revisão da literatura utilizando a base Medline/PubMed e literatura adicional. Resultados: O carcinoma hepatocelular é geralmente complicação da cirrose hepática. As hepatites virais crônicas B e C também são fatores de risco para o surgimento do carcinoma hepatocelular. Quando associado à cirrose hepática, o carcinoma hepatocelular geralmente surge a partir da evolução de um nódulo regenerativo hepatocitário que sofre degeneração maligna. O diagnóstico é efetuado através de tomografia computadorizada de abdome com contraste endovenoso (efeito wash in e wash out), e a ressonância magnética pode auxiliar nos casos que não possam ser definidos pela tomografia computadorizada. O único tratamento potencialmente curativo para o carcinoma hepatocelular é a ressecção do tumor, seja ela realizada através de hepatectomia parcial ou de transplante. Infelizmente, apenas cerca de 15% dos carcinomas hepatocelulares são passíveis de tratamento cirúrgico. Pacientes portadores de cirrose hepática estágio Child B e C não devem ser submetidos à ressecção hepática parcial. Para esses pacientes, as opções terapêuticas curativas restringem-se ao transplante de fígado, desde que selecionáveis para esse procedimento, o que na maioria dos países dá-se através dos Critérios de Milão (lesão única com até 5 cm de diâmetro ou até três lesões de até 3 cm de diâmetro). A sobrevida em 5 anos para pacientes transplantados para o carcinoma hepatocelular pode alcançar 70% Conclusão: Quando diagnosticado em seus estágios iniciais, o carcinoma hepatocelular é potencialmente curável. O conhecimento das estratégias de 17 diagnóstico e tratamento do carcinoma hepatocelular a fim propiciam sua identificação precoce e a indicação de tratamento apropriado. / Introduction: Hepatocellular carcinoma is an aggressive malignant tumor with high lethality. Aim: A literature review on diagnosis and management of hepatocellular carcinoma was performed. Methods: Literature review utilizing databases Medline/PubMed. Results: Hepatocellular carcinoma is a common complication of hepatic cirrhosis. Chronic viral hepatitis B and C also constitute as risk factors for development of hepatocellular carcinoma. In patients with cirrhosis, hepatocelular carcinoma usually develops from a malignant transformation of a dysplastic regenerative nodule. Diagnosis is confirmed through computed tomography scan with intravenous contrast (wash in and wash out effect), and magnetic resonance may be helpful in some instances. Curative treatment for hepatocellular carcinoma may be performed through partial liver resection or liver transplantation. Only 15% of all hepatocellular carcinomas are localized and amenable to operative treatment. Patients with Child C liver cirrhosis are not amenable to partial liver resections. The only curative treatment for hepatocellular carcinomas in patients with Child B or C cirrhosis is liver transplantation. In most countries, only patients with hepatocellular carcinoma under Milan Criteria (single tumor with up to 5 cm diameter or up to three nodules with a maximum diameter of 3 cm) are considered candidates for liver transplant. Five-year survival following liver transplantation for hepatocellular carcinoma may reach 70%. Conclusion: Hepatocellular carcinoma is a potentially curable neoplasm if discovered in its initial stages. Clinicians and surgeons should be familiar with strategies for early diagnosis and treatment of hepatocellular carcinoma as a way to decrease mortality associated with this malignant neoplasm.
|
165 |
Ação da melatonina sobre o estresse oxidativo e a angiogênese tumoral no modelo experimental de carcinogênese hepáticaNoda, Julie Matie January 2017 (has links)
Introdução: O carcinoma hepatocelular (CHC) é o câncer primário de fígado mais comum e está associado com a segunda menor taxa de sobrevida em 5 anos de todos os tipos de tumores. A melatonina (Mel) é uma potente molécula antioxidante que se tem mostrado benéfica em diversas situações patológicas, incluindo o CHC. Objetivo: Avaliar o efeito da Mel sobre marcadores de estresse oxidativo e angiogênicos no tecido hepático de ratos Wistar no modelo experimental de carcinogênese hepática induzida por dietilnitrosamina (DEN) associado ao acetilaminofluoreno (2-AAF). Métodos: 32 ratos machos Wistar (150g) foram divididos em 4 grupos: Controle (CO); Controle+Mel (CO+Mel); DEN e DEN+Mel. O DEN (50mg/kg) foi administrado por via intraperitoneal duas/uma vez por semana, associado a uma única dose de 2-AAF (100mg/kg). A Mel foi administrada na água de beber dos animais na concentração final de 20 mg/L e o tratamento teve início na 12ª semana perdurando até o fim das 19 semanas de experimento. O sangue dos animais foi coletado para as análises de AST, ALT, FA, γ-GT e amostras de fígado utilizadas para avaliar a lipoperoxidação (LPO), a atividade das enzimas antioxidantes (CAT, GPx e GST), os níveis de GSH e de metabólitos do óxido nítrico, a análise histógica e as proteínas envolvidas na angiogênese tumoral (VEGF, PI3K, p-Akt e eNOS). Resultados: O dano tecidual e o processo fibrogênico presentes no parênquima hepático estavam diminuídos no grupo DEN+Mel, assim como o nível de TBARS e a atividade da enzima GST quando comparados ao grupo DEN. A atividade da CAT mostrou-se aumentada no grupo DEN+Mel quando comparada ao grupo DEN. No processo angiogênio, a expressão de VEGF, PI3K, p-Akt mostrou-se diminuída no grupo DEN+Mel enquanto a expressão da eNOS apresentou-se aumentada quando comparado ao grupo DEN. Conclusão: Constatamos que a Mel foi capaz de minimizar os danos no parênquima hepático, de diminuir a LPO, modular a atividade da CAT, além de mostrar-se eficaz na redução de VEGF e da via PI3K/Akt no modelo experimental de carcinogênese hepática. / Background: Hepatocellular carcinoma (CHC) is the most common primary liver cancer and is associated with the second lowest 5-year survival rate of all tumor types. Melatonin (Mel) is a powerful antioxidant molecule that has been demonstrated to be beneficial in various pathological conditions, including HCC. Objective: The aim of this study was to evaluate the effect of Mel on oxidative stress and angiogenic markers in liver tissue of Wistar rats in the experimental model of hepatic carcinogenesis induced by diethylnitrosamine (DEN) and acetylaminofluorene (2-AAF). Methods: 32 male Wistar rats (150g) were divided into 4 groups: Control (CO); Control+Mel (CO+Mel); DEN and DEN+Mel. DEN (50mg/kg) was administered intraperitoneally once or twice a week, associated with a single dose of 2-AAF (100mg/kg). Mel was given in drinking water at the final concentration of 20 mg/L and the treatment was started at 12th week and continued until the end of the 19 weeks of experiment. Blood samples were collected for AST, ALT, AP, γ-GT and liver samples were used to evaluate lipid peroxidation (LPO), activity of antioxidant enzymes (CAT, GPx and GST), levels of GSH and nitric oxide levels, histological analysis and expression of proteins involved in tumor angiogenesis (VEGF, PI3K, p-Akt and eNOS). Results: The tissue damage and the fibrogenic process present in the hepatic parenchyma were decreased as well as the levels of TBARS and the activity of GST in the group DEN+Mel when compared to DEN group. CAT activity was increased in DEN+Mel group when we compared with DEN group. The expression of VEGF, PI3K, p-Akt was decreased in DEN+Mel group while eNOS expression was increased when compared to DEN group. Conclusion: Mel was able to minimize damage in the hepatic parenchyma, reduce LPO, modulate the activity of CAT and reduce VEGF and the PI3K/Akt pathway in a experimental model of hepatic carcinogenesis.
|
166 |
MicroRNoma dos carcinomas de fígadoAriede, Jovita Ramos. January 2017 (has links)
Orientador: Patricia Pintor dos Reis / Resumo: Introdução: O carcinoma hepatocelular (CHC) está entre as neoplasias de alta complexidade no diagnóstico, determinação do prognóstico e tratamento, sendo o sexto tipo de câncer mais comum no mundo e a segunda causa mais comum de morte por câncer. Uma variedade de genes alterados foram relatados, revelando heterogeneidade genética entre tumores de diferentes pacientes. Portanto, o insucesso terapêutico da terapia convencional pode ser parcialmente atribuído a essa heterogeneidade associada ao comportamento biológico tumoral. Sendo assim, justifica-se a necessidade de identificação de vias moleculares as quais podem conter biomarcadores clinicamente aplicáveis para a melhoria do diagnóstico e tratamento dos pacientes com CHC. Os resultados podem ter futuras aplicações clínicas utilizando miRNAs e os genes-alvo regulados por miRNAs como biomarcadores com valor diagnóstico, prognóstico e terapêutico. Objetivos: Identificar o perfil global de expressão de miRNAs (microRNoma) e os mRNAs-alvo potencialmente regulados por miRNAs em CHC. Pacientes e Métodos: Foram incluídas 18 amostras de tecido, fixadas em formalina e emblocadas em parafina (FFPE) de carcinoma hepatocelular, sendo 18 amostras tumorais e 18 amostras de tecido hepático histologicamente normal, adjacente ao tumor, dos mesmos pacientes. O perfil de expressão de miRNAs das amostras tumorais foi determinado utilizando o ensaio TaqMan Array Human MicroRAN Cards (TLDA) (card A) (Life Technologies). A análise dos dados util... (Resumo completo, clicar acesso eletrônico abaixo) / Doutor
|
167 |
Perfil transcricional da infecção crônica pelo vírus da Hepatite C (VHC) por sequenciamento de nova geração / Transcriptional profile of chronic hepatitis C virus (HCV) infection by next generation sequencingZugaib, Renata [UNESP] 13 January 2017 (has links)
Submitted by RENATA ZUGAIB null (rzugaib@gmail.com) on 2017-01-20T15:02:38Z
No. of bitstreams: 1
Dissertação Renata - Defesa.pdf: 1638667 bytes, checksum: f166690438b6f00c2e9fe2b0da55497d (MD5) / Approved for entry into archive by Juliano Benedito Ferreira (julianoferreira@reitoria.unesp.br) on 2017-01-24T18:09:13Z (GMT) No. of bitstreams: 1
zugaib_r_me_bot.pdf: 1638667 bytes, checksum: f166690438b6f00c2e9fe2b0da55497d (MD5) / Made available in DSpace on 2017-01-24T18:09:13Z (GMT). No. of bitstreams: 1
zugaib_r_me_bot.pdf: 1638667 bytes, checksum: f166690438b6f00c2e9fe2b0da55497d (MD5)
Previous issue date: 2017-01-13 / O vírus da hepatite C (VHC) constitui a principal causa de doença hepática crônica, que representa um dos maiores problemas de saúde pública. O carcinoma hepatocelular (CHC), altamente associado a infecção crônica pelo vírus da hepatite C (VHC), é um dos tumores malignos mais comuns no mundo, com um alto índice de causa de óbito. Com o avanço das técnicas moleculares, tornou-se possível uma nova abordagem nos estudos gênicos para um melhor entendimento molecular de processos infecciosos e crônicos. Estudos evidenciando uma associação da transcrição gênica ao processo patológico e a importância de análises mais abrangentes. O sequenciamento de nova geração fornece uma maneira poderosa para a avaliação global do transcriptoma com alta resolução e um menor custo, possibilitando uma análise do perfil transcricional da doença. Assim, este estudo teve por objetivo avaliar o perfil de expressão gênica diferencial de pacientes infectados pelo VHC com CHC e comparar com amostras de tecidos não tumorais através do sequenciamento em larga escala do transcriptoma, a fim de identificar potenciais biomarcadores de diagnóstico e prognóstico de CHC. Foram analisados três fragmentos de tecido tumoral e três fragmentos de tecido hepático não tumoral como controle através do sequenciamento de RNAs (RNA-Seq). Os resultados obtidos demonstraram uma expressão diferencial de 4.792 genes. Avaliando os 10 genes mais e menos expressos, foi observada uma grande associação de variações nesses genes em diversos tipos de tumores. Também foram observados, entre os menos expressos, genes intimamente relacionados a função hepática ou relacionados a componentes produzidos pelo fígado. Esses achados sugerem que COL11A1, SFRP4, SFRP2, LRRC15, CCL18, ADAMDEC1, COL1A1, COL10A1, CTHRC1 e OLR1, superexpressos, possam atuar juntos no processo tumoral servindo como marcadores moleculares tumorais, e que a presença do tumor possa provocar uma desregulação nos genes associados ao fígado aqui encontrados, contudo, estudos mais específicos devem ser conduzidos para a confirmação dessa hipótese. / Hepatitis C virus (HCV) is the leading cause of chronic liver disease, one of the major public health problems. Hepatocellular carcinoma (HCC), highly associated with chronic hepatitis C virus (HCV) infection, is one of the most common malignant tumors in the world, with a high cause of death. With the advancement of molecular techniques, a new approach in gene studies has become possible for a better molecular understanding of infectious and chronic processes. Studies evidencing an association of the gene transcription to the pathological process and the importance of more comprehensive analyzes. Next generation sequencing provides a powerful way for the global evaluation of the transcriptome with high resolution and a lower cost, allowing an analysis of the transcriptional profile of the disease. Thus, this study aimed to evaluate the differential gene expression profile of HCV infected patients in their highest degree of chronicity (HCC) and to compare with non-tumor tissue samples through large-scale sequencing of the transcriptome in order to identify potential biomarkers for diagnosis and prognosis of HCC. Three fragments of tumor tissue and three fragments of non-tumor liver tissue were analyzed through the sequencing of RNAs (RNA-Seq). The results obtained demonstrated a differential expression of 4.792 genes. Evaluating the 10 over and down regulated genes, a high association of variations in these genes was observed in several types of tumors. Among the least expressed, genes closely related to liver function or related to components produced by the liver were also observed. These findings suggest that COL11A1, SFRP4, SFRP2, LRRC15, CCL18, ADAMDEC1, COL1A1, COL10A1, CTHRC1 and OLR1, overexpressed, may act together in the tumor process serving as molecular tumor markers, and that the presence of the tumor may lead to dysregulation in the genes associated with the liver found here, however, more specific studies should be conducted to confirm this hypothesis.
|
168 |
Alcoolização e embolização arterial como terapias-ponte ao transplante hepático no tratamento do hepatocarcinoma relacionado ao vírus da hepatite CChedid, Márcio Fernandes January 2017 (has links)
Racional: O carcinoma hepatocelular é uma neoplasia maligna agressiva com elevada morbidade e mortalidade. Objetivo: Revisão da literatura sobre o diagnóstico e o manejo do carcinoma hepatocelular nos vários estágios da doença. Método: Revisão da literatura utilizando a base Medline/PubMed e literatura adicional. Resultados: O carcinoma hepatocelular é geralmente complicação da cirrose hepática. As hepatites virais crônicas B e C também são fatores de risco para o surgimento do carcinoma hepatocelular. Quando associado à cirrose hepática, o carcinoma hepatocelular geralmente surge a partir da evolução de um nódulo regenerativo hepatocitário que sofre degeneração maligna. O diagnóstico é efetuado através de tomografia computadorizada de abdome com contraste endovenoso (efeito wash in e wash out), e a ressonância magnética pode auxiliar nos casos que não possam ser definidos pela tomografia computadorizada. O único tratamento potencialmente curativo para o carcinoma hepatocelular é a ressecção do tumor, seja ela realizada através de hepatectomia parcial ou de transplante. Infelizmente, apenas cerca de 15% dos carcinomas hepatocelulares são passíveis de tratamento cirúrgico. Pacientes portadores de cirrose hepática estágio Child B e C não devem ser submetidos à ressecção hepática parcial. Para esses pacientes, as opções terapêuticas curativas restringem-se ao transplante de fígado, desde que selecionáveis para esse procedimento, o que na maioria dos países dá-se através dos Critérios de Milão (lesão única com até 5 cm de diâmetro ou até três lesões de até 3 cm de diâmetro). A sobrevida em 5 anos para pacientes transplantados para o carcinoma hepatocelular pode alcançar 70% Conclusão: Quando diagnosticado em seus estágios iniciais, o carcinoma hepatocelular é potencialmente curável. O conhecimento das estratégias de 17 diagnóstico e tratamento do carcinoma hepatocelular a fim propiciam sua identificação precoce e a indicação de tratamento apropriado. / Introduction: Hepatocellular carcinoma is an aggressive malignant tumor with high lethality. Aim: A literature review on diagnosis and management of hepatocellular carcinoma was performed. Methods: Literature review utilizing databases Medline/PubMed. Results: Hepatocellular carcinoma is a common complication of hepatic cirrhosis. Chronic viral hepatitis B and C also constitute as risk factors for development of hepatocellular carcinoma. In patients with cirrhosis, hepatocelular carcinoma usually develops from a malignant transformation of a dysplastic regenerative nodule. Diagnosis is confirmed through computed tomography scan with intravenous contrast (wash in and wash out effect), and magnetic resonance may be helpful in some instances. Curative treatment for hepatocellular carcinoma may be performed through partial liver resection or liver transplantation. Only 15% of all hepatocellular carcinomas are localized and amenable to operative treatment. Patients with Child C liver cirrhosis are not amenable to partial liver resections. The only curative treatment for hepatocellular carcinomas in patients with Child B or C cirrhosis is liver transplantation. In most countries, only patients with hepatocellular carcinoma under Milan Criteria (single tumor with up to 5 cm diameter or up to three nodules with a maximum diameter of 3 cm) are considered candidates for liver transplant. Five-year survival following liver transplantation for hepatocellular carcinoma may reach 70%. Conclusion: Hepatocellular carcinoma is a potentially curable neoplasm if discovered in its initial stages. Clinicians and surgeons should be familiar with strategies for early diagnosis and treatment of hepatocellular carcinoma as a way to decrease mortality associated with this malignant neoplasm.
|
169 |
Ação da melatonina sobre o estresse oxidativo e a angiogênese tumoral no modelo experimental de carcinogênese hepáticaNoda, Julie Matie January 2017 (has links)
Introdução: O carcinoma hepatocelular (CHC) é o câncer primário de fígado mais comum e está associado com a segunda menor taxa de sobrevida em 5 anos de todos os tipos de tumores. A melatonina (Mel) é uma potente molécula antioxidante que se tem mostrado benéfica em diversas situações patológicas, incluindo o CHC. Objetivo: Avaliar o efeito da Mel sobre marcadores de estresse oxidativo e angiogênicos no tecido hepático de ratos Wistar no modelo experimental de carcinogênese hepática induzida por dietilnitrosamina (DEN) associado ao acetilaminofluoreno (2-AAF). Métodos: 32 ratos machos Wistar (150g) foram divididos em 4 grupos: Controle (CO); Controle+Mel (CO+Mel); DEN e DEN+Mel. O DEN (50mg/kg) foi administrado por via intraperitoneal duas/uma vez por semana, associado a uma única dose de 2-AAF (100mg/kg). A Mel foi administrada na água de beber dos animais na concentração final de 20 mg/L e o tratamento teve início na 12ª semana perdurando até o fim das 19 semanas de experimento. O sangue dos animais foi coletado para as análises de AST, ALT, FA, γ-GT e amostras de fígado utilizadas para avaliar a lipoperoxidação (LPO), a atividade das enzimas antioxidantes (CAT, GPx e GST), os níveis de GSH e de metabólitos do óxido nítrico, a análise histógica e as proteínas envolvidas na angiogênese tumoral (VEGF, PI3K, p-Akt e eNOS). Resultados: O dano tecidual e o processo fibrogênico presentes no parênquima hepático estavam diminuídos no grupo DEN+Mel, assim como o nível de TBARS e a atividade da enzima GST quando comparados ao grupo DEN. A atividade da CAT mostrou-se aumentada no grupo DEN+Mel quando comparada ao grupo DEN. No processo angiogênio, a expressão de VEGF, PI3K, p-Akt mostrou-se diminuída no grupo DEN+Mel enquanto a expressão da eNOS apresentou-se aumentada quando comparado ao grupo DEN. Conclusão: Constatamos que a Mel foi capaz de minimizar os danos no parênquima hepático, de diminuir a LPO, modular a atividade da CAT, além de mostrar-se eficaz na redução de VEGF e da via PI3K/Akt no modelo experimental de carcinogênese hepática. / Background: Hepatocellular carcinoma (CHC) is the most common primary liver cancer and is associated with the second lowest 5-year survival rate of all tumor types. Melatonin (Mel) is a powerful antioxidant molecule that has been demonstrated to be beneficial in various pathological conditions, including HCC. Objective: The aim of this study was to evaluate the effect of Mel on oxidative stress and angiogenic markers in liver tissue of Wistar rats in the experimental model of hepatic carcinogenesis induced by diethylnitrosamine (DEN) and acetylaminofluorene (2-AAF). Methods: 32 male Wistar rats (150g) were divided into 4 groups: Control (CO); Control+Mel (CO+Mel); DEN and DEN+Mel. DEN (50mg/kg) was administered intraperitoneally once or twice a week, associated with a single dose of 2-AAF (100mg/kg). Mel was given in drinking water at the final concentration of 20 mg/L and the treatment was started at 12th week and continued until the end of the 19 weeks of experiment. Blood samples were collected for AST, ALT, AP, γ-GT and liver samples were used to evaluate lipid peroxidation (LPO), activity of antioxidant enzymes (CAT, GPx and GST), levels of GSH and nitric oxide levels, histological analysis and expression of proteins involved in tumor angiogenesis (VEGF, PI3K, p-Akt and eNOS). Results: The tissue damage and the fibrogenic process present in the hepatic parenchyma were decreased as well as the levels of TBARS and the activity of GST in the group DEN+Mel when compared to DEN group. CAT activity was increased in DEN+Mel group when we compared with DEN group. The expression of VEGF, PI3K, p-Akt was decreased in DEN+Mel group while eNOS expression was increased when compared to DEN group. Conclusion: Mel was able to minimize damage in the hepatic parenchyma, reduce LPO, modulate the activity of CAT and reduce VEGF and the PI3K/Akt pathway in a experimental model of hepatic carcinogenesis.
|
170 |
Rôles de la clathrine et de SMAP1 dans la signalisation et le trafic intracellulaire des récepteurs de la famille ErbB dans les carcinomes hépatocellulaires / Role of clathrin and SMAP1 in the signaling and intracellular trafficking of the ErbB family in hepatocellular carcinomasLiu, Yuanhui 30 October 2017 (has links)
Les carcinomes hépatocellulaires (CHC) sont la deuxième cause de décès par cancer dans le monde. La signalisation du récepteur du facteur de croissance épidermique (EGFR) joue un rôle au cours du développement des CHC. Il a été montré que le trafic intracellulaire régulait la signalisation des récepteurs de la famille ErbB dans les CHC. De façon intéressante, l'expression de la clathrine, un acteur majeur de l'endocytose, est anormalement élevée dans les CHC. Ainsi, les objectifs de nos travaux étaient de définir si l'endocytose module la signalisation de la famille des récepteurs ErbB en réponse à divers ligands. Les expériences ont été effectuées dans trois lignées cellulaires issues de CHC, qui expriment des niveaux variables des différents récepteurs ErbB. Nos résultats montrent que l'inhibition de l'expression de la clathrine par ARN interférence était associée à une diminution significative de la phosphorylation des récepteurs EGFR, ErbB2 et ErbB3. La phosphorylation de STAT3 était significativement augmentée dans toutes les lignées. Les conséquences de l'inhibition pharmacologique de la dynamine et de la régulation négative de SMAP1 par ARN interférence ont été étudiées dans la lignée Hep3B. L'inhibition de la dynamine entraînait une augmentation significative des niveaux de phosphorylation d'EGFR, d'ErbB3 et d'AKT, alors que SMAP1 ne jouait aucun rôle dans la signalisation. Au total, nos observations soulignent que la signalisation des récepteurs ErbB dans les CHC est un processus complexe qui dépend de l'expression des différents membres de la famille ErbB et de la disponibilité de leurs ligands dans l'environnement tumoral. / Hepatocellular carcinoma (HCC) is the second leading cause of death by cancer in the world. The epidermal growth factor receptor (EGFR) signalling axis plays a key role in HCC. Intracellular trafficking has been shown to regulate receptor signalling, and to be altered in HCC. Our aim was to investigate whether endocytosis may modulate signalling of the ErbB receptor family in response to various ligands. The experiments have been performed in three HCC cell lines, which express variable levels of ErbB receptors. We investigated the role of clathrin, dynamin, and SMAP1 (Small ArfGAP1). Our results show that the effects of down-regulating clathrin by siRNA varied among HCC cell lines, depending on the ligand. Upon clathrin down-regulation by RNA interference, EGFR phosphorylation decreased in Hep3B and in PLC/PRF/5 cells stimulated with AR, EGF or HB-EGF, as well as in HRG-stimulated PLC/PRF/5 cells. Clathrin inhibition decreased ErbB2 phosphorylation in HepG2 cells stimulated with EGF, HB-EGF or HRG, and in HRG-stimulated PLC/PRF/5 cells. Phosphorylation of ErbB3 significantly decreased in all cell lines upon stimulation with EGF, HB-EGF or HRG. STAT3 phosphorylation significantly increased in all cell lines. Dynamin inhibition by dynasore led to a significant increase in the phosphorylation levels of EGFR, ErbB3 and AKT, in the Hep3B cell line. SMAP1 played no role in the early signalling of ErbB receptors upon stimulation with whatever ligand. Altogether, our observations underline that ErbB signalling in HCC is a complex process that may depend on the expression of the various ErbB family members and on the availability of their ligands in the tumour environment.
|
Page generated in 0.0384 seconds